

Nanosphere™ Size Standards. Certified in billionths of a meter by Duke Scientific

Nanosphere Size Standards are calibrated in billionths of a meter (nanometers) and are available in 22 sizes from 21 to 900nm—all traceable to the National Bureau of Standards. Nanospheres are part of our complete line of spherical particles from 0.02 to 2000 micrometers in diameter. They are used as standards for instrument calibration, quality control, filter checking, and in numerous biotechnology applications. At Duke Scientific—established in 1971—we have the expertise and resources to meet any of your requirements for microspheres and particles. Call us today for information.



1135D San Antonio Road, Palo Alto, CA 94303, Toll Free
(800) 334-3883, in CA (415) 962-1100, Fax (415) 962-0718



Circle No. 22 on Readers' Service Card

WE'LL SHIP YOUR OLIGO IN 48 HOURS, OR WE'LL EAT THE NEXT ONE.

You get your primer or probe on time, or you get your next one for free. No questions, no quibbles. For \$5.00 a base (and \$20 setup charge), you'll receive a research-ready, cartridge-purified product, complete with PAGE gel pedigree. And you'll get it on time, or we'll be eating **GENO§YS** more than our words.

SPECIAL OFFER! Call **1-800-2345-DNA**, or fax a copy of this coupon, and we'll drop the setup charges on your first order. That's a savings of \$20 per oligo! (If you don't need any oligos at the moment, we'll send you a coupon for future use.)

Name _____ Title _____
Institution/Company _____
Address _____
City _____ State _____ Zip _____
Telephone _____

Genosys Biotechnologies, Inc. 8701A New Trails Drive, The Woodlands, Texas 77381-4241
Phone: (713) 363-3693 (800) 2345-DNA Fax: (713) 363-2212

Circle No. 3 on Readers' Service Card

feature of the corpse, but I propose an alternative hypothesis for the man's demise. My own experience is that the folded-over ear is a common consequence of having had too much to drink (substitute "state of complete inebriation" in the above quotation). Invariably, when one goes to bed in this state, he or she wakes up with a sore auricle. I thus propose that we cannot rule out the possibility that the Tyrolean man's downfall was indirectly attributable not to exhaustion, but to overconsumption of prehistoric schnapps.

George B. McManus

3175 Cumberland Road, Theodore, AL 36582

Response: McManus's hypothesis is not as improbable as it seems. His observations about the "folded-over ear" as a consequence of alcohol abuse have been described extensively (including radial nerve lesions resulting from lying in a nearly unconscious condition). However, our colleagues from the Institute for Alpine History Research at the University of Innsbruck have ascertained that no prehistoric bottle of spirits was found among the ice man's provisions. We therefore consider exhaustion to be a more likely cause of death than exposure to cold caused by intoxication.

McManus does not suggest the use of drugs, but we refer the reader to a paper by R. Pöder et al. (1) discussing pieces of two *Piptoporus betulinus*, an agaric, fastened to a leather band among the possessions of the ice man. These fungi may have been used for spiritual and medicinal purposes. They contain a pharmacologically active substance, agaricine acid, an antibiologically effective agent. To our knowledge, no hallucinogenic effects have been described for *P. betulinus*.

Horst Seidler

Institut für Humanbiologie,
Universität Wien, A-1091 Wien, Austria

REFERENCES

1. R. Pöder, U. Peintner, T. Pümpel, *Bericht über das Internationale Symposium "Der Mann im Eis—Ein Fund aus der Steinzeit Tirols,"* Innsbruck, Austria, 3 to 5 June 1972, K. Spindler, Ed. (Veröffentlichungen der Universität Innsbruck, vol. 187, 1992).



EMF Research

H. Keith Florig, in his Policy Forum "Containing the costs of the EMF problem" (24 July, p. 468), addresses a segment of a broad problem that besets society today. How should one deal with fears that are not known to be justified? Florig estimates that the avoidance of weak electromagnetic fields (EMFs) now costs the United States about \$1 billion annually, although there is no consensus that these fields, much small-

er than those occurring naturally in the body, can have any biological effects, let alone pose dangers.

Florig argues that more research on weak EMFs is economically justified inasmuch as that research is likely to either demonstrate that EMF dangers are real, allowing cost-effective decisions concerning mitigation, or show that the fields are harmless, thus eliminating avoidance costs. However, unless the new research differs in kind from that of the past 15 years, which I contend has created an imaginary problem where no real problem exists, one can expect only further obfuscation and higher costs to our society.

Past biological EMF research has often been misleading. Because there is no accepted model of the interactions of EMFs and the human body, experimental errors have been accepted as real effects. This is demonstrated by, and explains, the incoherence and lack of replication of the different positive reports and the almost universal lack of a dose-response relation.

Also the statistical significances of some of the biological work and many of the epidemiological reports have been seriously overstated. Such analyses are usually subjective; experience with simpler, falsifiable, physical science experiments has shown that significance levels are generally exaggerated.

There are further biases that emphasize false positives and suppress negatives. Results that are claimed to be positive are accepted for publication, while negative results are rejected as uninteresting—or as failures. And those who report positive results are more likely to have their funding renewed than those who “fail.”

What should be done? Much advice, such as Florig's, is marred by conflicts of interest. Better, the National Academy of Sciences, chartered by Congress for the purpose of advising the government, should be asked to evaluate the evidence on EMF effects and to recommend appropriate action.

Robert K. Adair

Department of Physics,
Yale University, New Haven, CT 06511

Response: Adair implies that the hundreds of articles in the peer-reviewed literature reporting statistically significant observations of EMF bioeffects are the result of uncontrolled artifacts, statistical false positives, or observational bias. While such factors have undoubtedly clouded the scientific record, many credentialed observers believe that the chance that EMF hazards are real is far from negligible. A large number of biologists and epidemiologists

Continued on page 1960

Mean calculations don't have to be so consuming.



No matter how you look at it, data analysis can be a real monster.

That's why GraphPad is pleased to introduce **InStat** and **InPlot**, powerful and easy-to-use scientific software that can really take a bite out of your workload.

InStat. Instant Biostatistics.

Unlike heavy-duty programs designed for statisticians, **InStat** is designed for *scientists*. Even if your knowledge of statistics is a bit rusty, **InStat**'s clear language makes it easy to calculate *t* tests, nonparametric tests, one-way ANOVA, chi-square, Fisher's test, linear regression and needed sample size. Not sure which test to use? Simply use the built-in help screens.

InPlot. Scientific Graphics.

InPlot makes it equally easy to quickly analyze your raw data and create polished graphs – complete with error bars, log axes and scientific symbols. Curve fitting with nonlinear regression has never been easier. There are even special features for radiogland binding and RIAs. And **InPlot** is so easy-to-learn, you can create your first graph in minutes.

Both programs are backed by an unconditional, 90-day guarantee and free technical support.*

Call (800) 388-4723 today for more information. Because analyzing data no longer has to be like pulling teeth.

GraphPad™

Intuitive software for science.

10855 Sorrento Valley Road, Suite 203 • San Diego, CA 92121 • USA
TEL. (800) 388-4723, (619) 457-3909 • FAX (619) 457-8141

***InPlot** costs \$395 and is a DOS program. **InStat** costs \$95 and is available in DOS and MAC versions.

News & Tips on Microscopy

THE ZEISS CORNER

NUMBER 3

Changing Arc Lamps

Arc lamps in mercury and xenon burners work under high vacuum and high temperatures. These safety steps are highly recommended.

- Wear safety glasses.
- Wear lint-free gloves or use lens tissue when handling the bare bulb.
- Let the burner cool completely before removing the bulb.
- Unplug the power supply.

PROCEDURE

1. Move collector lens away from bulb (knob on lamp housing) or remove lens entirely. Separate socket from lamp housing (retaining screw).
2. Remove copper wire from post (thumb screw) then pull bulb upwards from socket (loosen lug nut at base; special wrench). Remove heat sink (silver cap on bulb; set screw).
3. Reverse steps 1-2 to reinstall new bulb, being careful not to put strain or stress on bulb when tightening fittings. (For 50W HBO burners, make sure flat sealed surface is facing to side.)
4. To align arc, remove an objective, rotate empty space into viewing position and place a white card flat on stage, revealing real and mirror arc images. Focus images using collector lens and align (see diagram) using centering screws on lamp housing.



(L) HBO 50
(R) HBO 100,
XBO 75

5. Defocus images to evenly illuminate field; reinstall objective.

TIPS

- For greater stability, run for one hour before using.
- Never switch high pressure burners on and off quickly.

Send us your ideas for future issues of The Zeiss Corner. And for all your microscopy needs, contact Zeiss today.

SEE
WHAT
YOU'RE
MISSING

ZEISS

Microscope Division
Carl Zeiss, Inc.
One Zeiss Drive
Thornwood, NY 10594
Call: 800-233-2343
Fax: 914-681-7446

Continued from page 1869

contend that an equally plausible explanation of the record is that EMF bioeffects are simply more subtle than those of many other environmental agents and that, as lines of inquiry and scientific tools are sharpened through further research, uncertainties about possible EMF hazards will likely be reduced. Indeed, EMF bioeffects research funded by the Department of Energy and the Electric Power Research Institute has become much more focused over the last 5 years, reflecting knowledge gained through the previous decade.

Even if one concludes, like Adair, that the specter of EMF hazard is imaginary, there are still good reasons for expanding both the depth and breadth of EMF-related research. First, if the research record is indeed contaminated by artifact, an expanded research program that concentrates on experimental quality control and replication of existing positive studies would set the record straight. Second, public concerns and ad hoc expenditures on mitigation are driven primarily by several dozen nominally positive epidemiological studies of the relationship between EMF exposure and cancer. Further epidemiological investigation might "explain" these positive studies as arising from some non-EMF cause such as a yet-to-be-identified confounder. Third, public and private officials faced with EMF risk-management decisions are more likely to delay spending on EMF mitigation if they believe that continuing research might reduce uncertainty in their decision. Finally, accelerated research on the public's need for EMF information, on fair ways to resolve powerline siting disputes, and on low-cost means for reducing EMF exposures can reduce both contention over powerline siting and the risk of product liability suits. This would save the costs of transmission project delays and courtroom battles and would go farther toward relieving public angst than would a halt to all research.

Adair's prescription for managing the EMF issue raises another broad problem that besets society today. In a democratic society, who should decide what fears are justified? Adair would vest that power in the scientific community (or more specifically in a small elite such as a National Academy of Sciences committee). Although the public and policy-makers depend on scientists for judgments about the probability and scope of possible EMF hazards, the legitimacy of the scientist's expertise stops there. Decisions about the appropriate level of funding for EMF research or about whether to control EMF exposures require making value judgments about willingness to pay, risk aversion, and equity among other things (1). Such decisions require input from all stakeholders.

H. Keith Florig
Resources for the Future,
1616 P Street, NW,
Washington, DC 20036

REFERENCES

1. H. Otway, in *Social Theories of Risk*, S. Krimsky and D. Golding, Eds. (Praeger, Westport, CT, 1992), pp. 215-228.

Brain Tumor Treatment: Significant Contributions

In our report of 12 June (p. 1550), "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors" (1), we cited, among others, the papers of M. P. Short *et al.* (2) and Z. D. Ezzeddine *et al.* (3), which described studies of in situ delivery of the lacZ gene into C6 gliomas and the effect of ganciclovir treatment on the growth of subcutaneously implanted tumors that bear a herpes thymidine kinase gene. We have received a complaint from X. O. Breakefield, a co-author of those reports, that our method of referencing did not give sufficient credit to their work.

It was the intent of the citations included in our manuscript to serve as an acknowledgement of the contributions of other workers reporting studies in this area of research. We regret that a more detailed description of the work contained in each of the cited papers was not possible within the space allotted by *Science* for the text of our report. The citation and terse description included were in no way intended to diminish the significance of contributions by any of the cited workers. We are pleased to again acknowledge that other investigators have suggested a similar strategy for the treatment of malignant tumors of the brain and note that none had reported the successful implementation of this strategy.

R. Michael Blaese
Kenneth W. Culver
Hiroyuki Ishii

National Cancer Institute,
National Institutes of Health,
Bethesda, MD 20892

Edward H. Oldfield
Zvi Ram

Stuart Wallbridge
National Institute of Neurological
Disorders and Stroke,
National Institutes of Health

REFERENCES

1. K. W. Culver, Z. Ram, S. Wallbridge, H. Ishii, E. H. Oldfield, R. M. Blaese, *Science* **256**, 1550 (1992).
2. M. P. Short, B. C. Choi, J. K. Lee, A. Malick, X. O. Breakefield, R. L. Martuza, *J. Neurosci. Res.* **27**, 427 (1990).
3. Z. D. Ezzeddine, R. L. Martuza, D. Platika, M. P. Short, A. Malick, B. Choi, X. O. Breakefield, *New Biol.* **3**, 608 (1991).